Furthermore, we discovered that a low dose of NU7441 significantly reduced CSC enrichment in drug-resistant cancer cells, as shown by decreased expression of key markers of CSCs (ALDH1A1, KLF4, CD133, Nanog, and SOX9) (Fig. 5D) and diminished sphere formation ability (Fig. 5E). The gene discussed is ALDH1A1; the disease is cancer.